Rheumatology News and Research

RSS

Rheumatology is a sub-specialty in internal medicine and pediatrics, devoted to the diagnosis and therapy of rheumatic diseases. Rheumatologists mainly deal with clinical problems involving joints, soft tissues and allied conditions of connective tissues.

Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc., today announced results for the third quarter ended September 30, 2009.

28 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

UAB to create national database and repository to identify medications for rheumatoid arthritis

The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA).

24 Oct 2009

Study results of PTH1-34 oral parathyroid hormone presented

Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere’s proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.

22 Oct 2009

Collection of rheumatology research articles published

A comprehensive account of the most important advances in rheumatology research from the past decade has been published in BioMed Central's open access journal Arthritis Research and Therapy (AR&T). This freely available collection of 38 articles written by an internationally recognized group of experts spanning more than 400 pages is an essential educational tool which provides clinicians and researchers with a detailed overview of the current status of basic, translational and clinical research in rheumatology.

22 Oct 2009

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive™ (CRx-102) at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia. The data demonstrated that Synavive-treated subjects maintained efficacy levels throughout the 12 month extension trial.

21 Oct 2009

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb Company announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.

21 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

RA patients who adhere to their prescription drug regimen have better outcome: Study

Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia.

20 Oct 2009

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

AstraZeneca and POZEN Inc. today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

20 Oct 2009

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

NicOx S.A. announced the presentation of detailed 26-week efficacy, safety and tolerability data from the second pivotal phase 3 study for naproxcinod (the 302 study) yesterday, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

20 Oct 2009

Menarini granted exclusive European licence rights to Ipsen's Adenuric

Ipsen, an innovation-driven global specialty pharmaceutical group, announced an agreement whereby Ipsen grants the Menarini Group the exclusive licence rights to Adenuric® (febuxostat) in 41 countries. Ipsen retains co-promotion rights for Adenuric® in France.

20 Oct 2009

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC- (febuxostat) treatment.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Trubion Pharmaceuticals, Inc. today announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.

19 Oct 2009

Rheumatology News and Research

Further Reading

Third-quarter fiscal 2009 results announced by POZEN

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

UAB to create national database and repository to identify medications for rheumatoid arthritis

Study results of PTH1-34 oral parathyroid hormone presented

Collection of rheumatology research articles published

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

RA patients who adhere to their prescription drug regimen have better outcome: Study

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

Menarini granted exclusive European licence rights to Ipsen's Adenuric

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News